Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Helixmith Co., Ltd.

https://www.helixmith.com/

Latest From Helixmith Co., Ltd.

Helixmith Plunges On Warning Of Possible Offering Delay

Korean venture Helixmith faces another setback following a missed Phase III endpoint for its plasmid DNA neuropathy candidate, with its shares plunging after it warned of a possible delay in a planned rights offering, amid concerns from minority shareholders over other investment losses.

South Korea Financing

Korean Firms Pursue “Select And Focus” Strategy To Accelerate R&D

South Korean pharma and biotech companies are opting to spin off certain businesses and set up new subsidiaries to speed up R&D progress and tap funding opportunities. The move, which has become more visible in the past few years is in line with global biopharma trends, although the reasons may vary.

Research & Development South Korea

Helixmith Mods Engensis Trial Plans As Probe Unravels PK Anomalies

After probing pharmacokinetic data flaws in the first US Phase III study for its gene therapy Engensis, Korea's Helixmith concludes that these stemmed from clinical operation issues. As a result, it admits a failure to meet the primary endpoint but is still moving forward with new trials given signals of efficacy and safety in an extended study.

South Korea United States

Korea 2019 Review: Industry Spooked By Invossa Affair, Disappointing Trials But Hopes Intact

The South Korean pharma/biotech industry suffered a series of negative blows in 2019 but there were still notable achievements including major drug approvals and large-scale licensing deals.

South Korea Gene Therapy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Nutraceuticals
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • ViroMed Co., Ltd.
    • VM BioPharma
    • Genebiotech Co., Ltd
UsernamePublicRestriction

Register